日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Cupriavidus taiwanensis Protein translocase subunit SecA (secA), partial CSB-YP461390DZS
CSB-EP461390DZS
CSB-BP461390DZS
CSB-MP461390DZS
CSB-EP461390DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis Sec-independent protein translocase protein TatA (tatA), partial CSB-YP461391DZS
CSB-EP461391DZS
CSB-BP461391DZS
CSB-MP461391DZS
CSB-EP461391DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis 50S ribosomal protein L17 (rplQ) CSB-YP461392DZS
CSB-EP461392DZS
CSB-BP461392DZS
CSB-MP461392DZS
CSB-EP461392DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis 50S ribosomal protein L6 (rplF) CSB-YP461393DZS
CSB-EP461393DZS
CSB-BP461393DZS
CSB-MP461393DZS
CSB-EP461393DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis 30S ribosomal protein S3 (rpsC) CSB-YP461394DZS
CSB-EP461394DZS
CSB-BP461394DZS
CSB-MP461394DZS
CSB-EP461394DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis 50S ribosomal protein L4 (rplD) CSB-YP461395DZS
CSB-EP461395DZS
CSB-BP461395DZS
CSB-MP461395DZS
CSB-EP461395DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis DNA-directed RNA polymerase subunit beta (rpoB), partial CSB-YP461396DZS
CSB-EP461396DZS
CSB-BP461396DZS
CSB-MP461396DZS
CSB-EP461396DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis Periplasmic nitrate reductase (napA), partial CSB-YP461397DZS
CSB-EP461397DZS
CSB-BP461397DZS
CSB-MP461397DZS
CSB-EP461397DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Cupriavidus taiwanensis Ribulose bisphosphate carboxylase large chain (cbbL) CSB-YP461398DZS
CSB-EP461398DZS
CSB-BP461398DZS
CSB-MP461398DZS
CSB-EP461398DZS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Arrestin-related trafficking adapter 10 (ART10), partial CSB-YP461399SVP
CSB-EP461399SVP
CSB-BP461399SVP
CSB-MP461399SVP
CSB-EP461399SVP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rotavirus A Non-structural protein 2 CSB-YP461400ROB
CSB-EP461400ROB
CSB-BP461400ROB
CSB-MP461400ROB
CSB-EP461400ROB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rotavirus A Non-structural protein 2 CSB-YP461401RNV
CSB-EP461401RNV
CSB-BP461401RNV
CSB-MP461401RNV
CSB-EP461401RNV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rotavirus A Non-structural protein 1 CSB-YP461402ROG
CSB-EP461402ROG
CSB-BP461402ROG
CSB-MP461402ROG
CSB-EP461402ROG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rotavirus A Non-structural protein 5 CSB-YP461403ROL
CSB-EP461403ROL
CSB-BP461403ROL
CSB-MP461403ROL
CSB-EP461403ROL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nosema bombycis Spore wall protein 30 (SWP32) CSB-YP461404NHN
CSB-EP461404NHN
CSB-BP461404NHN
CSB-MP461404NHN
CSB-EP461404NHN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Brachypodium distachyon Ribulose bisphosphate carboxylase large chain (rbcL) CSB-YP461405BVS
CSB-EP461405BVS
CSB-BP461405BVS
CSB-MP461405BVS
CSB-EP461405BVS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Brachypodium distachyon 50S ribosomal protein L14, chloroplastic (rpl14) CSB-YP461406BVS
CSB-EP461406BVS
CSB-BP461406BVS
CSB-MP461406BVS
CSB-EP461406BVS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Brachypodium distachyon Maturase K (matK), partial CSB-YP461407BVS
CSB-EP461407BVS
CSB-BP461407BVS
CSB-MP461407BVS
CSB-EP461407BVS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oedogonium cardiacum 30S ribosomal protein S19, chloroplastic (rps19) CSB-YP461408ODX
CSB-EP461408ODX
CSB-BP461408ODX
CSB-MP461408ODX
CSB-EP461408ODX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rana dybowskii Temporin-CDYe CSB-YP461409RJK
CSB-EP461409RJK
CSB-BP461409RJK
CSB-MP461409RJK
CSB-EP461409RJK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶(hù)提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€(xiàn)留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×